{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-019639","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.281598+00:00","generated_at":"2026-05-16T00:47:02.562555+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adial Pharmaceuticals regains Nasdaq minimum bid price compliance; highlights advanced AD04 partnering discussions","bullets":["Received Nasdaq notice on Feb. 23, 2026 that closing bid price was ≥$1.00 for 10 consecutive business days (Feb. 6-20, 2026).","Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.","CEO Cary Claiborne stated the company is engaged in advanced strategic partnering discussions for AD04.","AD04 is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder, moving toward Phase 3 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-019639","json":"https://secwatch.observer/filing/0001213900-26-019639.json","markdown":"https://secwatch.observer/filing/0001213900-26-019639.md","text":"https://secwatch.observer/filing/0001213900-26-019639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026019639/0001213900-26-019639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026019639/ea0278114-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:47:02.562555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}